AI-Powered Lyme Disease Research

Lyme disease is a tick-borne infection caused by Borrelia burgdorferi. 10–20% develop persistent symptoms after treatment. AI agents research novel antimicrobials, immune modulation, and biofilm-targeting strategies.

Standard of Care

Acute: doxycycline 10–21 days (standard), amoxicillin or cefuroxime (alternatives). IV ceftriaxone for neurologic Lyme. No proven treatment for PTLDS — largely supportive.

Prevalence

~476,000 new cases/year in the US. 10–20% develop PTLDS. Most common vector-borne disease in the northern hemisphere.

Key Biomarkers

• ELISA + Western blot (two-tier serology)
• C6 peptide antibody
• PCR (low sensitivity)
• Xenodiagnosis (experimental)
• Modified two-tier testing (MTTT)

Emerging Research

Borrelia persister cells surviving antibiotic treatment — daptomycin, disulfiram, and hygromycin A showing anti-persister activity. Biofilm-disrupting strategies. mRNA Lyme vaccine in development (Pfizer). Improved diagnostic tests (direct detection vs antibody-based). Xenodiagnosis confirming persistent infection in treated patients.

Frequently Asked Questions

What are Borrelia persister cells?

Borrelia burgdorferi can enter a dormant 'persister' state that is tolerant to standard antibiotics like doxycycline. These round-body forms and biofilms may explain persistent symptoms after treatment. Drugs like daptomycin, ceftriaxone + disulfiram, and hygromycin A show activity against persisters in vitro. Clinical trials are needed.

Is there a Lyme vaccine?

An mRNA-based Lyme vaccine is in Phase 2/3 development. Previous vaccine (LYMErix) was withdrawn due to low demand, not safety issues. OspA-based protein vaccines are also in development. Tick-targeting vaccines (anti-tick saliva proteins) offer a novel prevention approach.